# MRD-Directed Consolidation With Epcor-only or Epcor-R2 Post Anti-CD19 CAR TCell Therapy for Large B-Cell Lymphoma

> **NCT06414148** · PHASE2 · RECRUITING · sponsor: **Peter MacCallum Cancer Centre, Australia** · enrollment: 40 (estimated)

## Conditions studied

- Relapsed/Refractory Large B-cell Lymphoma

## Interventions

- **DRUG:** Epcoritamab
- **DRUG:** Epcoritamab, lenalidomide and rituximab

## Key facts

- **NCT ID:** NCT06414148
- **Lead sponsor:** Peter MacCallum Cancer Centre, Australia
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2024-05-14
- **Primary completion:** 2026-10
- **Final completion:** 2028-05
- **Target enrollment:** 40 (ESTIMATED)
- **Last updated:** 2025-06-05

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06414148

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06414148, "MRD-Directed Consolidation With Epcor-only or Epcor-R2 Post Anti-CD19 CAR TCell Therapy for Large B-Cell Lymphoma". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT06414148. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*